Geftinat 250mg Tablets
Geftinat is a targeted therapy, it is a generic (analogous) preparation of Iress- which has a high anticancer activity. The original tool is designed and manufactured in the US. Geftinat and Iressa have the same active substance, thus having similar properties, the only difference is the cost (Buy online at Emedkit at affordable prices). Geftinat (Gefitnib) 250mg Tablet is prescription anticancer medicine that is manufactured by Natco Pharma Limited. It functions by interfering with the growth and spread of cancer cells in the body
Brief Description of the Anticancer Agent
Title: Geftinat 250 mg.
Country of origin: India.
Manufacturer: Natco Pharma Limited.
The proprietary name of the developer: Iressa (USA, AstraZeneca Pharmaceuticals LP).
Status of the medicinal product: Generic.
Dosage: 250 mg.
The active substance of cytostatic action: Gefitinib.
Packing content: 30 tablets.
Indication for use in non-small cell lung cancer-in a locally advanced form or with metastases:
The first line of chemotherapy is used in the presence of the receptors of EGF (epidermal growth factor) mutations of the tyrosine kinase domain.
As a second-line drug, Gefitinib 250 mg is used in the progression of a tumor after an unsuccessful first line of chemotherapy or against its background, if the first line was carried out with drugs that contain derivatives of platinum or docetaxel, and as a result, the immunity of cancer cells to used drugs. It is also approved as a drug of the third line of therapy.
It is rare that non-small cell lung cancer is diagnosed in the early stages – 1st and 2nd when the disease is easier to treat. More than 40% of cases are diagnosed of the fourth stage of the disease with metastases. In this case, therapy involves increasing the patient’s life expectancy, improving the quality of life by getting rid of symptoms, since there is practically no chance of a complete cure. Such a therapy is conservative.
Gefitinib refers to drugs with relatively low toxicity, so it can be used to treat weakened and elderly patients.
You can buy Gefitinib online in some pharmacies (such as Emedkit) that have contracts for direct shipments with the manufacturer, directly on the manufacturer’s website, we have issued an international delivery for countries USA, Russia, Peru, Romania and China; or in the country of production. However, do not forget that this drug is dispensed by prescription.
Geftinat 250 mg Gefitinib components:
Compositions of generic Geftinat and the original preparation of Iress are almost identical.
Gefitinib 250 mg is an active ingredient. It is an inhibitor of the hyperactive trans-membrane receptor of a particular protein, which stimulates cell growth, and mutations of which lead to the formation of cancer cells.
Lactose monohydrate (245 mg) is a filler of a dosage form. It is used due to its low cost, high stability, and weak hygroscopicity.
Microcrystalline cellulose (67 mg) is an emulsifier and a filler of a dosage form. - Emedkit
Croscarmellose sodium (20 mg) is a disintegrant of the dosage form. It is used to increase the solubility of the active substance; it ensures a high bioavailability of the drug.
Sodium lauryl sulfate (6 mg) is a binder component, ensuring uniform mixing of dissimilar ingredients.
Magnesium stearate (7 mg) is a stabilizer, a thickener and a filler of a dosage form.
Polyvinylpyrrolidone K-30 (5 mg) is a binder that increases the solubility and bioavailability of the active ingredient.
The composition of the envelope includes the following components: 60% – hypromellose, 23% – titanium dioxide, 12% – polyethylene glycol, less than 5% – talc, less than 0.1% in aggregate – iron oxide red and yellow.
The composition Geftinat 250 Gefitinib provides the maximum possible bioavailability of the drug, directed action. The shell allows maintaining the integrity and shape of the tablet, and also provides a gradual and long-term dissolution of the tablets.
Uses of Geftinat 250 mg Gefitinib:
The main effect of Gefitinib is focussed on blocking tyrosine kinase in the receptors of the epidermal growth factor.
This mechanism allows achieving the following results: inhibition of tumor growth, a decrease in the probability or a slowing down of the rates of metastasis, inhibition of angiogenesis, and acceleration of apoptosis of tumor cells.
The list of useful properties of Geftinat 250 mg Gefitinib also includes an increase in the antitumor activity of other chemotherapeutic drugs, along with the effectiveness of hormonal and radiotherapy is also increasing. Therefore, complex treatment takes precedence.
Do not forget that the effect of Gefitinib is associated with an increase in the time of progression of the disease, i.e., an increase in the timing of remission or a period of relapse. These data are confirmed statistically.
Gefitinib dominantly differs from some similar drugs with less toxicity which allows in reducing the list of contraindications and their side effects. Due to this during the treatment, the patient’s quality of life is an order of magnitude higher than that of other drugs. However, this aspect does not affect the overall level of survival in the direction of decrease, so the performance indicators are at a sufficiently high level.
The objective response at the second and third lines of therapy is about 19%, which is almost 2.5 times more than with docetaxel. On the third and fourth lines of therapy, this indicator is lower and ranges from 9 to 12%. In this case, symptomatic improvement occurs already in the first days of chemotherapy.
A high degree of effectiveness is ensured by the optimal bioavailability of the drug, the average of which is 59%. However, it should be noted that the volume distribution of the active substance indicates its extensive nature. In other words, from the excessive increase in the amount of the drug in the tissues, its effectiveness does not increase.
The statistics are as follows: an increase in the daily dosage twice, ie, up to 500 mg, does not lead to an increase in efficacy, but increases the toxicity of therapy, the risk of side effects and the level of total intoxication of the body.
An interesting fact: the antitumor effect is more often recorded in those patients who, during the treatment of Geftinat 250 Gefitinib, had a side effect such as a skin rash.
Chemotherapy is associated with a high risk of intoxication of the body, which affects the vital organs, worsening the general well-being of the patient. Due to this, any antitumor drug has a number of contraindications and can have some side effect, worsening the quality of life.
The most important contraindication is self-medication. After all, the patient is not able to assess the benefit-harm ratio of this medication. Before applying, a thorough examination by a medical specialist in oncology is required, which will carry out the necessary diagnostic procedures, take into account the general condition of the patient and prescribe additional medications or medical procedures. The therapy should also take place under the supervision of a doctor.
The main contraindications are:
During pregnancy, the period of gestation and lactation, children’s age until the age of 18 and the presence of allergies to the active substance or ancillary components.
Instructions for Use Geftinat 250 Gefitinib:
The daily dosage of the active ingredient of the anti-cancer drug Geftinat is 250 mg. It is prescribed regardless of the patient’s condition, age, sexual or racial affiliation, kidney function or liver failure in either of two forms (moderate or severe) associated with metastatic liver damage, body weight.
The missed dose can be consumed only if there are more than 12 hours remaining until the next tablet is taken.
It is forbidden to exceed the daily dose, as this is fraught with increased toxicity of the drug.
You should not divide the pill into parts and consume it as a whole.
Short-term interruption of treatment is possible which may result in poorly treatable diarrhoea, as well as negative reactions on the skin. The duration of the break should not exceed 14 days. The resumption of the course of therapy occurs with an initial dosage of 250 mg.
The drug is taken regardless of the food intake; food does not affect its bioavailability. It should be ensured that the bioavailability of the drug is affected by the high acidity level of the gastric juice, reducing the index to 47%.
During the therapy and within 3-4 months after the treatment ends, the patient and his sexual partner should use reliable contraceptives.
Instructions are intended to familiarize patients with the effect of the drug and are not a recommended for self-treatment.
This is custom tab. You can add custom tab as an attribute for entire products, or for each categories. You can add CMS content such as sizing guide or videos to enhance product detail.